abemaciclib

Ligand id: 7382

Name: abemaciclib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 75
Molecular weight 506.27
XLogP 4.19
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
LY2835219 has reached Phase 3 clinical trial for non-small cell lung cancer and breast cancer. Additional clinical trials are underway for treatment of lymphomas. LY2835219 is being evaluated either alone or in combination with other antineoplastics. Click here to link to a complete list of ClinicalTrials.gov's registered LY2835219 trials.
In July 2017, the FDA granted Priority Review for abemaciclib as a potential treatment for advanced breast cancer, in particular for HR+, HER2- disease.
Mechanism Of Action and Pharmacodynamic Effects
The CDK4/6 pathway is key to regulating cell growth in many types of human cancer [1,7-8], such as genetic subtypes of non-small cell lung cancer (NSCLC, [2,7,9], melanoma, Mantle cell lymphoma (MCL), and ovarian and breast cancers [2-3]. CDK4/6 inhibitors are designed to interfere with this pathway to ultimately prevent cell cycle transition from G1 to S phase, induce cell senescence and in some cases cause apoptosis [2].
In some breast cancers the cyclin D1-CDK4 pathway appears to mediate resistance to HER2-directed therapies. Abemaciclib is able to re-sensitise such resistant tumours to conventional HER2 blockers [5].
Abemaciclib's developer, Eli Lilly has produced a mechanism of action infographic which you can access here.